Publications in collaboration with researchers from Hospital General Universitario Gregorio Marañón (170)

2024

  1. Childhood-Onset Non-Infectious Uveitis in the “Biologic Era”. Results From Spanish Multicenter Multidisciplinary Real-World Clinical Settings

    Ocular Immunology and Inflammation, Vol. 32, Núm. 9, pp. 2159-2169

  2. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER)

    Rheumatology International, Vol. 44, Núm. 11, pp. 2445-2455

  3. Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  4. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

  5. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  6. Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis

    Reumatologia Clinica, Vol. 20, Núm. 8, pp. 423-439

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  3. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

    Advances in Rheumatology, Vol. 63, Núm. 1

  4. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

    Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197

  5. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 61

  6. Proposal for updating the Health Assessment Questionnaire

    Reumatologia Clinica, Vol. 19, Núm. 5, pp. 266-272

  7. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology

    Reumatologia Clinica, Vol. 19, Núm. 2, pp. 74-81

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study

    Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 217-224

  3. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  4. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies

    RMD open, Vol. 8, Núm. 1

  5. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology

    Reumatologia Clinica, Vol. 18, Núm. 5, pp. 253-259

  6. Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry

    Musculoskeletal Care, Vol. 20, Núm. 2, pp. 403-407

2021

  1. Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: A systematic review

    Immunotherapy, Vol. 13, Núm. 5, pp. 433-458